According to the ESC guidelines, cangrelor may be considered in P2Y12-inhibitor-naïve acute coronary syndrome (ACS) patients undergoing percutaneous coronary intervention (PCI). The aim of this review is to summarize available evidence on the optimal maintenance therapy with P2Y12 receptor inhibitor after cangrelor. Transitioning from cangrelor to a thienopyridine, but not ticagrelor, can be associated with a drug-drug interaction (DDI); therefore, a ticagrelor loading dose (LD) can be given any time before, during, or at the end of a cangrelor infusion, while a LD of clopidogrel or prasugrel should be administered at the time the infusion of cangrelor ends or within 30 minutes before the end of infusion in the case of a LD of prasugrel. Administration of any oral antiplatelet agent at the end of a cangrelor infusion will also result in a transient period of increased platelet reactivity. The inter-individual variability of this period is difficult to predict because it depends on many factors related to the patient and the treatment. In addition, experimental studies indicate that cangrelor may exert a cardioprotective effect beyond the blockade of platelet aggregation. Considering the available data, the potential use of cangrelor in ACS patients goes well beyond the current indications. Furthermore, we believe that it might be prudent to avoid use of thienopyridines during and soon after a cangrelor infusion until conclusive data on the effect of the DDI on the clinical outcome are available. On the other hand, ticagrelor seems to be an optimal oral agent for continuation of P2Y12 inhibition in patients receiving cangrelor infusion.

Cardiocenter 3rd Faculty of Medicine Charles University University Hospital Kralovske Vinohrady Prague Czech Republic

CAU Thrombosis and Biomarker Center Heart and Brain Hospital Chung Ang University Gwangmyeong Hospital Gwangmyeong Korea

Centre for Health Services Research School of Life and Medical Sciences University of Hertfordshire Hatfield Hertfordshire United Kingdom

Chair of the Cardiology Clinic Ward and Acute Cardiac Care Unit L Rydygier Provincial Integrated Hospital Torun Poland

Departement of Cardiology Baku Medical Plaza Hospitals Azerbaijan

Department of Cardiac Rehabilitation and Health Promotion Collegium Medicum Nicolaus Copernicus University Bydgoszcz Poland

Department of Cardiology and Internal Medicine Collegium Medicum Nicolaus Copernicus University Bydgoszcz Poland

Department of Cardiology Interventional Cardiology and Electrophysiology with Cardiac Intensive Care Unit Tertiary Care Hospital in Grudziadz Poland

Department of Cardiology Medical University of Gdansk Gdańsk Poland

Department of Cardiology Medical University of Vienna Austria

Department of Cardiology Provincial Hospital Elblag Poland

Department of Clinical and Interventional Cardiology Sassari University Hospital Sassari Italy

Department of Experimental and Clinical Pharmacology Medical University of Warsaw Poland

Department of Internal Medicine Chung Ang University College of Medicine Seoul Korea

Division of Cardiology and Department of Medicine University of Alberta Edmonton Canada

Faculty of Medicine National Heart and Lung Institute Imperial College London United Kingdom

Gajda Med District Hospital in Pultusk Poland

Henry JN Taub Department of Emergency Medicine Baylor College of Medicine Houston Houston TX USA

Institute of Outcomes Research Maria Sklodowska Curie Medical Academy Warsaw Poland

Sinai Center for Thrombosis Research Sinai Hospital of Baltimore Baltimore MD USA

Sinai Center for Thrombosis Research Sinai Hospital of Baltimore USA

See more in PubMed

Collet JP, Thiele H, Barbato E, et al. ESC Scientific Document Group. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2021;42(14):1289–1367. doi: 10.1093/eurheartj/ehaa575. PubMed DOI

Byrne RA, Rossello X, Coughlan JJ, et al. ESC Scientific Document Group. 2023 ESC Guidelines for the management of acute coronary syndromes. Eur Heart J. 2023;44(38):3720–3826. doi: 10.1093/eurheartj/ehad191. PubMed DOI

Wiviott SD, Braunwald E, McCabe CH, et al. TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357(20):2001–2015. doi: 10.1056/NEJMoa0706482. PubMed DOI

Wallentin L, Becker RC, Budaj A, et al. PLATO Investigators. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361(11):1045–1057. doi: 10.1056/NEJMoa0904327. PubMed DOI

Kubica J, Adamski P, Paciorek P, et al. Treatment of patients with acute coronary syndrome: Recommendations for medical emergency teams: Focus on antiplatelet therapies. Updated experts’ standpoint. Cardiol J. 2018;25(3):291–300. doi: 10.5603/CJ.a2018.0042. PubMed DOI

Kubica J, Adamski P, Ładny JR, et al. Pre-hospital treatment of patients with acute coronary syndrome: Recommendations for medical emergency teams. Expert position update 2022. Cardiol J. 2022;29(4):540–552. doi: 10.5603/CJ.a2022.0026. PubMed DOI PMC

Hudzik B, Błachut A, Lesiak M, et al. Summary of the European Society of Cardiology guidelines on dual antiplatelet therapy in patients after percutaneous coronary interventions. Kardiol Pol. 2022;80(10):974–989. doi: 10.33963/KP.a2022.0198. PubMed DOI

Adamski P, Sikora J, Laskowska E, et al. Comparison of bioavailability and antiplatelet action of ticagrelor in patients with ST-elevation myocardial infarction and non-ST-elevation myocardial infarction: A prospective, observational, single-centre study. PLoS One. 2017;12(10):e0186013. doi: 10.1371/journal.pone.0186013. PubMed DOI PMC

Agrawal K, Bhatt DL. Antiplatelet therapy: Does prasugrel or ticagrelor suffice in patients with STEMI? Nat Rev Cardiol. 2013;10(3):121–122. doi: 10.1038/nrcardio.2012.199. PubMed DOI

Schoergenhofer C, Hobl EL, Staudinger T, et al. Prasugrel in critically ill patients. Thromb Haemost. 2017;117(8):1582–1587. doi: 10.1160/TH17-03-0154. PubMed DOI PMC

Adamski P, Buszko K, Sikora J, et al. Determinants of high platelet reactivity in patients with acute coronary syndromes treated with ticagrelor. Sci Rep. 2019;9(1):3924. doi: 10.1038/s41598-019-40628-0. PubMed DOI PMC

Aradi D, Collet JP, Mair J, et al. Study Group on Biomarkers in Cardiology of the Acute Cardiovascular Care Association of the European Society of Cardiology, Working Group on Thrombosis of the European Society of Cardiology. Platelet function testing in acute cardiac care — is there a role for prediction or prevention of stent thrombosis and bleeding? Thromb Haemost. 2015;113(2):221–230. doi: 10.1160/TH14-05-0449. PubMed DOI

Kubica J, Pstrągowski K, Adamski P, et al. Mild therapeutic hypothermia for patients with acute coronary syndrome and cardiac arrest treated with percutaneous coronary intervention (UNICORN). The design and rationale for the prospective, observational, multicenter study. Me Res J. 2016;1(1):23–27. doi: 10.5603/mrj.2016.0004. DOI

Umiñska JM, Ratajczak J, Buszko K, et al. Impact of mild therapeutic hypothermia on bioavailability of ticagrelor in patients with acute myocardial infarction after out-of-hospital cardiac arrest. Cardiol J. 2020;27(6):780–788. doi: 10.5603/CJ.a2019.0024. PubMed DOI PMC

Bednar F, Kroupa J, Ondrakova M, et al. Antiplatelet efficacy of P2Y12 inhibitors (prasugrel, ticagrelor, clopidogrel) in patients treated with mild therapeutic hypothermia after cardiac arrest due to acute myocardial infarction. J Thromb Thrombolysis. 2016;41(4):549–555. doi: 10.1007/s11239-015-1274-7. PubMed DOI

Flierl U, Röntgen P, Zauner F, et al. Platelet inhibition with prasugrel in patients with acute myocardial infarction undergoing therapeutic hypothermia after cardiopulmonary resuscitation. Thromb Haemost. 2016;115(5):960–968. doi: 10.1160/TH15-07-0599. PubMed DOI

Umiñska JM, Ratajczak J, Pstrągowski K, et al. The impact of mild therapeutic hypothermia on platelet reactivity in comatose survivors of cardiac arrest with acute myocardial infarction treated with ticagrelor. Cardiol J. 2024;31(3):472–478. doi: 10.5603/CJ.a2022.0029. PubMed DOI PMC

Kubica J, Adamski P, Ostrowska M, et al. Morphine delays and attenuates ticagrelor exposure and action in patients with myocardial infarction: the randomized, double-blind, placebo-controlled IMPRESSION trial. Eur Heart J. 2016;37(3):245–252. doi: 10.1093/eurheartj/ehv547. PubMed DOI PMC

Kubica J, Kubica A, Jilma B, et al. Impact of morphine on antiplatelet effects of oral P2Y12 receptor inhibitors. Int J Cardiol. 2016;215:201–208. doi: 10.1016/j.ijcard.2016.04.077. PubMed DOI

Bartko J, Schoergenhofer C, Schwameis M, et al. Morphine Interaction with Aspirin: a Double-Blind, Crossover Trial in Healthy Volunteers. J Pharmacol Exp Ther. 2018;365(2):430–436. doi: 10.1124/jpet.117.247213. PubMed DOI

Kubica J, Adamski P, Ostrowska M, et al. Influence of Morphine on Pharmacokinetics and Pharmacodynamics of Ticagrelor in Patients with Acute Myocardial Infarction (IMPRESSION): study protocol for a randomized controlled trial. Trials. 2015;16:198. doi: 10.1186/s13063-015-0724-z. PubMed DOI PMC

Siller-Matula JM, Specht S, Kubica J, et al. Abciximab as a bridging strategy to overcome morphine-prasugrel interaction in STEMI patients. Br J Clin Pharmacol. 2016;82(5):1343–1350. doi: 10.1111/bcp.13053. PubMed DOI PMC

Ferreiro JL, Ueno M, Angiolillo DJ. Cangrelor: a review on its mechanism of action and clinical development. Expert Rev Cardiovasc Ther. 2009;7(10):1195–1201. doi: 10.1586/erc.09.101. PubMed DOI

Akers WS, Oh JJ, Oestreich JH, et al. Pharmacokinetics and pharmacodynamics of a bolus and infusion of cangrelor: a direct, parenteral P2Y12 receptor antagonist. J Clin Pharmacol. 2010;50(1):27–35. doi: 10.1177/0091270009344986. PubMed DOI

Adamski P, Adamska U, Ostrowska M, et al. New directions for pharmacotherapy in the treatment of acute coronary syndrome. Expert Opin Pharmacother. 2016;17(17):2291–2306. doi: 10.1080/14656566.2016.1241234. PubMed DOI

Kubica J, Kozinski M, Navarese EP, et al. Cangrelor: an emerging therapeutic option for patients with coronary artery disease. Curr Med Res Opin. 2014;30(5):813–828. doi: 10.1185/03007995.2014.880050. PubMed DOI

Bhatt DL, Lincoff AM, Gibson CM, et al. CHAMPION PLATFORM Investigators. Intravenous platelet blockade with cangrelor during PCI. N Engl J Med. 2009;361(24):2330–2341. doi: 10.1056/NEJMoa0908629. PubMed DOI

Harrington RA, Stone GW, McNulty S, et al. Platelet inhibition with cangrelor in patients undergoing PCI. N Engl J Med. 2009;361(24):2318–2329. doi: 10.1056/NEJMoa0908628. PubMed DOI

Tantry U, Chaudhary R, Kubica J, et al. Cangrelor for the treatment of patients with Arterial Thrombosis. Expert Opin Pharmacother. 2018;19(12):1389–1398. doi: 10.1080/14656566.2018.1506767. PubMed DOI

Niezgoda P, Ostrowska M, Adamski P, et al. Pretreatment with P2Y Receptor Inhibitors in Acute Coronary Syndromes-Is the Current Standpoint of ESC Experts Sufficiently Supported? J Clin Med. 2023;12(6) doi: 10.3390/jcm12062374. PubMed DOI PMC

Kangrexal EPAR summary for the public. [15.05.2023]. https://www.ema.europa.eu/en/medicines/human/EPAR/kengrexal .

Lawton JS, Tamis-Holland JE, Bangalore S, et al. Writing Committee Members. 2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2022;79(2):e21–e2e129. doi: 10.1016/j.jacc.2021.09.006. PubMed DOI

Cangrelor United States full prescribing information. [15.05.2023]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/204958lbl.pdf .

Valgimigli M, Bueno H, Byrne RA, et al. ESC Scientific Document Group, ESC Committee for Practice Guidelines (CPG), ESC National Cardiac Societies. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS) Eur Heart J. 2018;39(3):213–260. doi: 10.1093/eurheartj/ehx419. PubMed DOI

Montalescot G, van ‘t Hof AW, Lapostolle F, et al. ATLANTIC Investigators. Prehospital ticagrelor in ST-segment elevation myocardial infarction. N Engl J Med. 2014;371(11):1016–1027. doi: 10.1056/NEJMoa1407024. PubMed DOI

Silvain J, Storey RF, Cayla G, et al. P2Y12 receptor inhibition and effect of morphine in patients undergoing primary PCI for ST-segment elevation myocardial infarction. The PRIVATE-ATLANTIC study. Thromb Haemost. 2016;116(2):369–378. doi: 10.1160/TH15-12-0944. PubMed DOI

Lapostolle F, Van’t Hof AW, Hamm CW, et al. ATLANTIC Investigators. Morphine and Ticagrelor Interaction in Primary Percutaneous Coronary Intervention in ST-Segment Elevation Myocardial Infarction: ATLANTIC-Morphine. Am J Cardiovasc Drugs. 2019;19(2):173–183. doi: 10.1007/s40256-018-0305-0. PubMed DOI

Ostrowska M, Kubica J, Adamski P, et al. Stratified Approaches to Antiplatelet Therapies Based on Platelet Reactivity Testing. Front Cardiovasc Med. 2019;6:176. doi: 10.3389/fcvm.2019.00176. PubMed DOI PMC

Adamski P, Adamska U, Ostrowska M, et al. Evaluating current and emerging antithrombotic therapy currently available for the treatment of acute coronary syndrome in geriatric populations. Expert Opin Pharmacother. 2018;19(13):1415–1425. doi: 10.1080/14656566.2018.1510487. PubMed DOI

Yang XM, Liu Y, Cui L, et al. Platelet P2Y blockers confer direct postconditioning-like protection in reperfused rabbit hearts. J Cardiovasc Pharmacol Ther. 2013;18(3):251–262. doi: 10.1177/1074248412467692. PubMed DOI PMC

Yang XM, Liu Y, Cui L, et al. Two classes of anti-platelet drugs reduce anatomical infarct size in monkey hearts. Cardiovasc Drugs Ther. 2013;27(2):109–115. doi: 10.1007/s10557-012-6436-7. PubMed DOI PMC

Adamski P, Koziñski M, Ostrowska M, et al. Overview of pleiotropic effects of platelet P2Y12 receptor inhibitors. Thromb Haemost. 2014;112(2):224–242. doi: 10.1160/TH13-11-0915. PubMed DOI

Angiolillo DJ, Rollini F, Storey RF, et al. International Expert Consensus on Switching Platelet P2Y Receptor-Inhibiting Therapies. Circulation. 2017;136(20):1955–1975. doi: 10.1161/CIRCULATIONAHA.117.031164. PubMed DOI

Schneider DJ, Agarwal Z, Seecheran N, et al. Pharmacodynamic effects during the transition between cangrelor and ticagrelor. JACC Cardiovasc Interv. 2014;7(4):435–442. doi: 10.1016/j.jcin.2013.08.017. PubMed DOI

Schneider DJ, Seecheran N, Raza SS, et al. Pharmacodynamic effects during the transition between cangrelor and prasugrel. Coron Artery Dis. 2015;26(1):42–48. doi: 10.1097/MCA.0000000000000158. PubMed DOI

Steinhubl SR, Oh JJ, Oestreich JH, et al. Transitioning patients from cangrelor to clopidogrel: pharmacodynamic evidence of a competitive effect. Thromb Res. 2008;121(4):527–534. doi: 10.1016/j.thromres.2007.05.020. PubMed DOI

Dovlatova NL, Jakubowski JA, Sugidachi A, et al. The reversible P2Y antagonist cangrelor influences the ability of the active metabolites of clopidogrel and prasugrel to produce irreversible inhibition of platelet function. J Thromb Haemost. 2008;6(7):1153–1159. doi: 10.1111/j.1538-7836.2008.03020.x. PubMed DOI

Karaźniewicz-Łada M, Danielak D, Burchardt P, et al. Clinical pharmacokinetics of clopidogrel and its metabolites in patients with cardiovascular diseases. Clin Pharmacokinet. 2014;53(2):155–164. doi: 10.1007/s40262-013-0105-2. PubMed DOI PMC

Wang H, Qi J, Li Yi, et al. Pharmacodynamics and pharmacokinetics of ticagrelor vs. clopidogrel in patients with acute coronary syndromes and chronic kidney disease. Br J Clin Pharmacol. 2018;84(1):88–96. doi: 10.1111/bcp.13436. PubMed DOI PMC

Dobesh PP. Pharmacokinetics and pharmacodynamics of prasugrel, a thienopyridine P2Y12 inhibitor. Pharmacotherapy. 2009;29(9):1089–1102. doi: 10.1592/phco.29.9.1089. PubMed DOI

Judge HM, Buckland RJ, Jakubowski JA, et al. Cangrelor inhibits the binding of the active metabolites of clopidogrel and prasugrel to P2Y12 receptors in vitro. Platelets. 2016;27(3):191–195. doi: 10.3109/09537104.2015.1069809. PubMed DOI

Rymer JA, Bhatt DL, Angiolillo DJ, et al. Cangrelor Use Patterns and Transition to Oral P2Y Inhibitors Among Patients With Myocardial Infarction: Initial Results From the CAMEO Registry. J Am Heart Assoc. 2022;11(11):e024513. doi: 10.1161/JAHA.121.024513. PubMed DOI PMC

Ravnefjord A, Weilitz J, Emanuelsson BM, et al. Evaluation of ticagrelor pharmacodynamic interactions with reversibly binding or non-reversibly binding P2Y(12) antagonists in an ex-vivo canine model. Thromb Res. 2012;130(4):622–628. doi: 10.1016/j.thromres.2012.07.021. PubMed DOI

Adamski P, Skonieczny G, Hajdukiewicz T, et al. Reversal of Platelet Inhibition in Patients Receiving Ticagrelor. Rev Cardiovasc Med. 2022;23(9):300. doi: 10.31083/j.rcm2309300. PubMed DOI PMC

Schneider DJ. Transition strategies from cangrelor to oral platelet P2Y12 receptor antagonists. Coron Artery Dis. 2016;27(1):65–69. doi: 10.1097/MCA.0000000000000311. PubMed DOI